Germany’s Bayer (BAYN: DE) is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the USA to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia A treatment, Jivi, antihemophilic factor (recombinant) PEGylated-aucl 3000 IU.
Despite the announcement, shares of Bayer were up 2.65% at 61.18 euros by early afternoon today.
The USA is the only country where affected products were distributed, and Bayer says it is working closely with the US Food and Drug Administration to manage the recall and to minimize disruption to supply and inconvenience to patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze